Thalidomide: all 323 studies that test it
Page 2 of 4. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.
- The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing ChemotherapyStatus unknownNCT03601871Not applicable
- Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for TransplantationCompletedNCT03402295Phase 3
- EGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideStatus unknownNCT03341494Phase 2
- Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic FactorsTerminatedNCT03221166Phase 3
- The Therapeutic Effect of Thalidomide in RIStatus unknownNCT03208413Phase 2
- The Effective and Safety of Thalidomide in TIStatus unknownNCT03184844Phase 2
- Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory MyelomaStatus unknownNCT03143036Phase 2
- Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT03140943Phase 2
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisActive, not recruitingNCT03069326Phase 2
- Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)Status unknownNCT03062800Phase 2
- Thalidomide Maintenance Treatment in DLBCLStatus unknownNCT03016000Phase 3
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD PatientsStatus unknownNCT02998827Not applicable
- The Effective and Safety of Thalidomide in NTDTStatus unknownNCT02995707Phase 2
- Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac AmyloidosisStatus unknownNCT02966522Phase 2
- Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using ThalidomideStatus unknownNCT02956538Early Phase 1
- Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance StrategyCompletedNCT02891811Phase 2
- EDOCH Alternating With DHAP for New Diagnosed Younger MCLCompletedNCT02858804Phase 4
- The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WMCompletedNCT02844309Phase 4
- Conmana Combined With Thalidomide to Treat NSCLCStatus unknownNCT02778893Phase 4
- Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related BleedingWithdrawnNCT02754960Phase 2
- Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT02733380Phase 2
- the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular MalformationCompletedNCT02707484Phase 3
- Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast CancerStatus unknownNCT02649101Phase 2
- STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTSCompletedNCT02586038Phase 2
- Thalidomide in Treating Crohn's DiseaseCompletedNCT02501291Phase 2
- Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02410694Phase 2
- Irinotecan Plus Thalidomide in Second Line Advanced Gastric CancerStatus unknownNCT02401971Phase 4
- Gefitinib Combined With Thalidomide to Treat NSCLCStatus unknownNCT02387086Phase 2/3
- Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course TreatmentWithdrawnNCT02301949Phase 2
- Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and VomitingCompletedNCT02203253Phase 3
- Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing SpondylitisCompletedNCT02201043Phase 2
- Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple MyelomaStatus unknownNCT02145715Phase 1/2
- PEG-ASP+Gemox Regimen and Thalidomide for NK/T LymphomaStatus unknownNCT02085655Phase 3
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedNCT01998971Phase 1
- High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITPWithdrawnNCT01976195Phase 2
- Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)CompletedNCT01971658Phase 3
- Pharmacokinetic Study of Thalidomide in Subjects With Multiple MyelomaCompletedNCT01937442Phase 1
- Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular CarcinomaStatus unknownNCT01924624Not applicable
- Thalidomide in the Treatment of Chronic Plaque Psoriasis.CompletedNCT01891019Phase 2
- ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic TumorsCompletedNCT01756989Phase 2
- Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid TumorsCompletedNCT01661400Phase 1
- THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt FailureStatus unknownNCT01640639Phase 4
- Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent ImplantationStatus unknownNCT01638078Phase 4
- Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal CancerStatus unknownNCT01551641Phase 2
- Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 YearsStatus unknownNCT01532856Phase 3
- Risk-adapted Therapy for Primary Systemic (AL) AmyloidosisCompletedNCT01527032Phase 2
- Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MMCompletedNCT01526694Phase 2
- Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic TelangiectasiaCompletedNCT01485224Phase 2
- THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)CompletedNCT01341262Phase 2
- Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple MyelomaCompletedNCT01296503Phase 3
- A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple MyelomaCompletedNCT01274403Phase 2
- Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaStatus unknownNCT01249690Phase 4
- Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)Status unknownNCT01114048Phase 2
- Thalidomide for Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownNCT01094340Phase 2/3
- Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.CompletedNCT01070862Phase 3
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma PatientsCompletedNCT01063179Phase 3
- S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT01055301Phase 2
- Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With EndometriosisTerminatedNCT01028781Phase 1
- RMPT for Relapsed/Refractory Multiple MyelomaCompletedNCT00961467Phase 2
- Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell LymphomaStatus unknownNCT00958854Phase 2
- A Study of High-Risk Oral Cavity CancerTerminatedNCT00934739Phase 2/3
- Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple MyelomaCompletedNCT00934154Phase 3
- Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular CarcinomaStatus unknownNCT00921531Phase 3
- Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal CancerStatus unknownNCT00890188Phase 2
- Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior TherapyActive, not recruitingNCT00871013Phase 2
- UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionActive, not recruitingNCT00869232Phase 2
- Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon ResistanceStatus unknownNCT00856804Phase 2
- Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDEWithdrawnNCT00787436Phase 3
- Thalidomide in Treating Patients With Relapsed or Progressive Systemic MastocytosisCompletedNCT00769587
- Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaStatus unknownNCT00728078Phase 2/3
- S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom MacroglobulinemiaWithdrawnNCT00723658Phase 2
- Thalidomide in Pediatric Inflammatory Bowel Diseases.CompletedNCT00720538Phase 3
- Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)Status unknownNCT00704704Phase 2
- Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple MyelomaCompletedNCT00657488Phase 2/3
- Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
- Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple MyelomaTerminatedNCT00644306Phase 3
- Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)CompletedNCT00633542Phase 3
- Thalidomide Versus Bortezomib in Melphalan Refractory MyelomaCompletedNCT00602511Phase 3
- A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)WithdrawnNCT00577668Phase 2
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total TherapyActive, not recruitingNCT00572169Phase 3
- Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma PatientsCompletedNCT00527657Phase 1
- Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent GlioblastomaStatus unknownNCT00521482Phase 2
- UFUR Plus Thalidomide for Advanced Hepatocellular CarcinomaCompletedNCT00519688Phase 2
- Safety and Efficacy Study of Thalomid in Patients With Chronic PancreatitisTerminatedNCT00469703Phase 2
- Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200CompletedNCT00455910Phase 2
- Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple MyelomaCompletedNCT00452569Phase 3
- Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate CancerTerminatedNCT00450008Phase 2
- Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid MetaplasiaCompletedNCT00445900Phase 2
- GEM05 for Patients With Multiple Myeloma More Than 65 Years OldCompletedNCT00443235Phase 3
- Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple MyelomaStatus unknownNCT00438841Phase 2
- Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic SclerosisTerminatedNCT00418132Phase 1
- Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma PatientsCompletedNCT00406978Phase 1/2
- Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis PatientsWithdrawnNCT00390247Phase 4
- Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingCompletedNCT00389935Phase 2
- Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma PatientsCompletedNCT00373646Phase 2
- Treatment of Newly Diagnosed Elderly Patients With Multiple MyelomaCompletedNCT00367185Phase 3
- Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma PatientsCompletedNCT00358020Phase 2
- TCD Followed by autoSCT for Newly Diagnosed MM PatientsStatus unknownNCT00349115Phase 2
- PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple MyelomaStatus unknownNCT00319865Phase 2